Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors

Aslamuzzaman Kazi, Shengyan Xiang, Hua Yang, Liwei Chen, Perry Kennedy, Muhammad Ayaz, Steven Fletcher, Christopher Cummings, Harshani R. Lawrence, Francisca Beato, Ya'an Kang, Michael P. Kim, Andrea Delitto, Patrick W. Underwood, Jason B. Fleming, Jose G. Trevino, Andrew Hamilton, Said M. Sebti

Research output: Contribution to journalArticle

Abstract

Purpose: Mutant KRAS is a major driver of pancreatic oncogenesis and therapy resistance, yet KRAS inhibitors are lacking in the clinic. KRAS requires farnesylation for membrane localization and cancer-causing activity prompting the development of farnesyltransferase inhibitors (FTIs) as anticancer agents. However, KRAS becomes geranylgeranylated and active when cancer cells are treated with FTIs. To overcome this geranylgeranylation-dependent resistance to FTIs, we designed FGTI-2734, a RAS C-terminal mimetic dual FT and geranylgeranyltransferase-1 inhibitor (GGTI). Experimental Design: Immunofluorescence, cellular fractionation, and gel shift assays were used to assess RAS membrane association, Western blotting to evaluate FGTI-2734 effects on signaling, and mouse models to demonstrate its antitumor activity. Results: FGTI-2734, but not the selective FTI-2148 and GGTI-2418, inhibited membrane localization of KRAS in pancreatic, lung, and colon human cancer cells. FGTI-2734 induced apoptosis and inhibited the growth in mice of mutant KRAS-dependent but not mutant KRAS-independent human tumors. Importantly, FGTI-2734 inhibited the growth of xenografts derived from four patients with pancreatic cancer with mutant KRAS (2 G12D and 2 G12V) tumors. FGTI-2734 was also highly effective at inhibiting, in three-dimensional cocultures with resistance promoting pancreatic stellate cells, the viability of primary and metastatic mutant KRAS tumor cells derived from eight patients with pancreatic cancer. Finally, FGTI-2734 suppressed oncogenic pathways mediated by AKT, mTOR, and cMYC while upregulating p53 and inducing apoptosis in patient-derived xenografts in vivo. Conclusions: The development of this novel dual FGTI overcomes a major hurdle in KRAS resistance, thwarting growth of patient-derived mutant KRAS-driven xenografts from patients with pancreatic cancer, and as such it warrants further preclinical and clinical studies.

Original languageEnglish (US)
Pages (from-to)5984-5996
Number of pages13
JournalClinical Cancer Research
Volume25
Issue number19
DOIs
StatePublished - Oct 1 2019

Fingerprint

Farnesyltranstransferase
Transferases
Pancreatic Neoplasms
Heterografts
Prenylation
Neoplasms
Membranes
Pancreatic Stellate Cells
Growth
Apoptosis
Coculture Techniques
Antineoplastic Agents
Colonic Neoplasms
Fluorescent Antibody Technique
Cell Survival
Carcinogenesis
Research Design
Western Blotting
Gels
Lung

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors. / Kazi, Aslamuzzaman; Xiang, Shengyan; Yang, Hua; Chen, Liwei; Kennedy, Perry; Ayaz, Muhammad; Fletcher, Steven; Cummings, Christopher; Lawrence, Harshani R.; Beato, Francisca; Kang, Ya'an; Kim, Michael P.; Delitto, Andrea; Underwood, Patrick W.; Fleming, Jason B.; Trevino, Jose G.; Hamilton, Andrew; Sebti, Said M.

In: Clinical Cancer Research, Vol. 25, No. 19, 01.10.2019, p. 5984-5996.

Research output: Contribution to journalArticle

Kazi, A, Xiang, S, Yang, H, Chen, L, Kennedy, P, Ayaz, M, Fletcher, S, Cummings, C, Lawrence, HR, Beato, F, Kang, Y, Kim, MP, Delitto, A, Underwood, PW, Fleming, JB, Trevino, JG, Hamilton, A & Sebti, SM 2019, 'Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors', Clinical Cancer Research, vol. 25, no. 19, pp. 5984-5996. https://doi.org/10.1158/1078-0432.CCR-18-3399
Kazi, Aslamuzzaman ; Xiang, Shengyan ; Yang, Hua ; Chen, Liwei ; Kennedy, Perry ; Ayaz, Muhammad ; Fletcher, Steven ; Cummings, Christopher ; Lawrence, Harshani R. ; Beato, Francisca ; Kang, Ya'an ; Kim, Michael P. ; Delitto, Andrea ; Underwood, Patrick W. ; Fleming, Jason B. ; Trevino, Jose G. ; Hamilton, Andrew ; Sebti, Said M. / Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors. In: Clinical Cancer Research. 2019 ; Vol. 25, No. 19. pp. 5984-5996.
@article{1c3eb177d290467b96b991f9f8febc59,
title = "Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors",
abstract = "Purpose: Mutant KRAS is a major driver of pancreatic oncogenesis and therapy resistance, yet KRAS inhibitors are lacking in the clinic. KRAS requires farnesylation for membrane localization and cancer-causing activity prompting the development of farnesyltransferase inhibitors (FTIs) as anticancer agents. However, KRAS becomes geranylgeranylated and active when cancer cells are treated with FTIs. To overcome this geranylgeranylation-dependent resistance to FTIs, we designed FGTI-2734, a RAS C-terminal mimetic dual FT and geranylgeranyltransferase-1 inhibitor (GGTI). Experimental Design: Immunofluorescence, cellular fractionation, and gel shift assays were used to assess RAS membrane association, Western blotting to evaluate FGTI-2734 effects on signaling, and mouse models to demonstrate its antitumor activity. Results: FGTI-2734, but not the selective FTI-2148 and GGTI-2418, inhibited membrane localization of KRAS in pancreatic, lung, and colon human cancer cells. FGTI-2734 induced apoptosis and inhibited the growth in mice of mutant KRAS-dependent but not mutant KRAS-independent human tumors. Importantly, FGTI-2734 inhibited the growth of xenografts derived from four patients with pancreatic cancer with mutant KRAS (2 G12D and 2 G12V) tumors. FGTI-2734 was also highly effective at inhibiting, in three-dimensional cocultures with resistance promoting pancreatic stellate cells, the viability of primary and metastatic mutant KRAS tumor cells derived from eight patients with pancreatic cancer. Finally, FGTI-2734 suppressed oncogenic pathways mediated by AKT, mTOR, and cMYC while upregulating p53 and inducing apoptosis in patient-derived xenografts in vivo. Conclusions: The development of this novel dual FGTI overcomes a major hurdle in KRAS resistance, thwarting growth of patient-derived mutant KRAS-driven xenografts from patients with pancreatic cancer, and as such it warrants further preclinical and clinical studies.",
author = "Aslamuzzaman Kazi and Shengyan Xiang and Hua Yang and Liwei Chen and Perry Kennedy and Muhammad Ayaz and Steven Fletcher and Christopher Cummings and Lawrence, {Harshani R.} and Francisca Beato and Ya'an Kang and Kim, {Michael P.} and Andrea Delitto and Underwood, {Patrick W.} and Fleming, {Jason B.} and Trevino, {Jose G.} and Andrew Hamilton and Sebti, {Said M.}",
year = "2019",
month = "10",
day = "1",
doi = "10.1158/1078-0432.CCR-18-3399",
language = "English (US)",
volume = "25",
pages = "5984--5996",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors

AU - Kazi, Aslamuzzaman

AU - Xiang, Shengyan

AU - Yang, Hua

AU - Chen, Liwei

AU - Kennedy, Perry

AU - Ayaz, Muhammad

AU - Fletcher, Steven

AU - Cummings, Christopher

AU - Lawrence, Harshani R.

AU - Beato, Francisca

AU - Kang, Ya'an

AU - Kim, Michael P.

AU - Delitto, Andrea

AU - Underwood, Patrick W.

AU - Fleming, Jason B.

AU - Trevino, Jose G.

AU - Hamilton, Andrew

AU - Sebti, Said M.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Purpose: Mutant KRAS is a major driver of pancreatic oncogenesis and therapy resistance, yet KRAS inhibitors are lacking in the clinic. KRAS requires farnesylation for membrane localization and cancer-causing activity prompting the development of farnesyltransferase inhibitors (FTIs) as anticancer agents. However, KRAS becomes geranylgeranylated and active when cancer cells are treated with FTIs. To overcome this geranylgeranylation-dependent resistance to FTIs, we designed FGTI-2734, a RAS C-terminal mimetic dual FT and geranylgeranyltransferase-1 inhibitor (GGTI). Experimental Design: Immunofluorescence, cellular fractionation, and gel shift assays were used to assess RAS membrane association, Western blotting to evaluate FGTI-2734 effects on signaling, and mouse models to demonstrate its antitumor activity. Results: FGTI-2734, but not the selective FTI-2148 and GGTI-2418, inhibited membrane localization of KRAS in pancreatic, lung, and colon human cancer cells. FGTI-2734 induced apoptosis and inhibited the growth in mice of mutant KRAS-dependent but not mutant KRAS-independent human tumors. Importantly, FGTI-2734 inhibited the growth of xenografts derived from four patients with pancreatic cancer with mutant KRAS (2 G12D and 2 G12V) tumors. FGTI-2734 was also highly effective at inhibiting, in three-dimensional cocultures with resistance promoting pancreatic stellate cells, the viability of primary and metastatic mutant KRAS tumor cells derived from eight patients with pancreatic cancer. Finally, FGTI-2734 suppressed oncogenic pathways mediated by AKT, mTOR, and cMYC while upregulating p53 and inducing apoptosis in patient-derived xenografts in vivo. Conclusions: The development of this novel dual FGTI overcomes a major hurdle in KRAS resistance, thwarting growth of patient-derived mutant KRAS-driven xenografts from patients with pancreatic cancer, and as such it warrants further preclinical and clinical studies.

AB - Purpose: Mutant KRAS is a major driver of pancreatic oncogenesis and therapy resistance, yet KRAS inhibitors are lacking in the clinic. KRAS requires farnesylation for membrane localization and cancer-causing activity prompting the development of farnesyltransferase inhibitors (FTIs) as anticancer agents. However, KRAS becomes geranylgeranylated and active when cancer cells are treated with FTIs. To overcome this geranylgeranylation-dependent resistance to FTIs, we designed FGTI-2734, a RAS C-terminal mimetic dual FT and geranylgeranyltransferase-1 inhibitor (GGTI). Experimental Design: Immunofluorescence, cellular fractionation, and gel shift assays were used to assess RAS membrane association, Western blotting to evaluate FGTI-2734 effects on signaling, and mouse models to demonstrate its antitumor activity. Results: FGTI-2734, but not the selective FTI-2148 and GGTI-2418, inhibited membrane localization of KRAS in pancreatic, lung, and colon human cancer cells. FGTI-2734 induced apoptosis and inhibited the growth in mice of mutant KRAS-dependent but not mutant KRAS-independent human tumors. Importantly, FGTI-2734 inhibited the growth of xenografts derived from four patients with pancreatic cancer with mutant KRAS (2 G12D and 2 G12V) tumors. FGTI-2734 was also highly effective at inhibiting, in three-dimensional cocultures with resistance promoting pancreatic stellate cells, the viability of primary and metastatic mutant KRAS tumor cells derived from eight patients with pancreatic cancer. Finally, FGTI-2734 suppressed oncogenic pathways mediated by AKT, mTOR, and cMYC while upregulating p53 and inducing apoptosis in patient-derived xenografts in vivo. Conclusions: The development of this novel dual FGTI overcomes a major hurdle in KRAS resistance, thwarting growth of patient-derived mutant KRAS-driven xenografts from patients with pancreatic cancer, and as such it warrants further preclinical and clinical studies.

UR - http://www.scopus.com/inward/record.url?scp=85072819941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072819941&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-3399

DO - 10.1158/1078-0432.CCR-18-3399

M3 - Article

C2 - 31227505

AN - SCOPUS:85072819941

VL - 25

SP - 5984

EP - 5996

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 19

ER -